Genetic determinants of response to warfarin during initial anticoagulation. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM (2008) N Engl J Med 358: 999-1008 Estimation of the warfarin dose with clinical and pharmacogenetic data. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA (2009) N Engl J Med 360: 753-64 Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D (2009) Blood 113: 3925-30 Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. Chan KE, Lazarus JM, Thadhani R, Hakim RM (2009) J Am Soc Nephrol 20: 2223-33 Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. Chan KE, Lazarus JM, Thadhani R, Hakim RM (2009) J Am Soc Nephrol 20: 872-81 Genetic determinants of variability in warfarin response after the dose-titration phase. Iwuchukwu OF, Ramirez AH, Shi Y, Bowton EA, Kawai VK, Schildcrout JS, Roden DM, Denny JC, Stein CM (2016) Pharmacogenet Genomics 26: 510-516 Warfarin pharmacogenomics in children. Vear SI, Stein CM, Ho RH (2013) Pediatr Blood Cancer 60: 1402-7
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.